[Studies on enzymeimmunoassay for human chorionic gonadotropin and its clinical application].
Two enzyme immunoassays for hCG were developed and compared with HAR and RIA by using many urine and serum samples. The EIA was characterized by management of trophoblastic disease. 1. An EIA by hCG-beta antibody immobilized on a microplate and hCG antibody conjugated with HRP enzyme quantified hCG from 0.5 to 100ng/ml, while the other by biotinyl hCG antibody and avidine-HRP conjugate quantified hCG from 0.1 to 20ng/ml. Both of them had a good correlation with RIA; y = 1.02x + 2.3, r=0.99 and Y=0.96x-0.38. The C.V.S. were 1.8 and 5.2% (intraassay), or 5.8 and 9.5% (interassay), respectively. 2. The EIA was carried out to test hCG patients whose urinary hCG by HAR was under the LH level. The values in 371 samples were under 2ng/ml, but those in 40 samples were higher than 2ng/ml (Max 15.8 ng/ml). Diagnosis by EIA distinguished recurrence from remission 2 month earlier than by HAR. The EIA was useful in the management of the disease.
D000328:Adult; D006063:Chorionic Gonadotropin / Q000032:analysis*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007124:Immunoenzyme Techniques; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D011247:Pregnancy; D014328:Trophoblastic Neoplasms / Q000032:analysis; D014594:Uterine Neoplasms / Q000032:analysis
D006063:Chorionic Gonadotropin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone